Physician profile
David Alvarez
NPI 1871578385
$7,081.72
in general payments reported to CMS, 2019-2025
12 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,562 · 2020: $148 · 2022: $124 · 2023: $29.90 · 2024: $104 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $6,477.62 | 2019 | |
| Abbott Laboratories | $130.78 | 2020 | |
| Galderma Laboratories, L.P. | $123.75 | 2022 | |
| Abbvie INC. | $76.39 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $62.10 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.56 | 2025 | Lifevest |
| Pfizer INC. | $53.04 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $42.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.65 | 2023 | Xarelto |
| Melinta Therapeutics, LLC | $14.41 | 2019 | |
| Merck Sharp & Dohme LLC | $14.25 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.